Jazz Pharmaceuticals (HAM:J7Z) Valuation Rank


HAM:J7Z Jazz Pharmaceuticals PLC HAM:J7Z
73 GF Score
Price €209.50
GF Value €127.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Jazz Pharmaceuticals Valuation Rank Related Terms

HAM:J7Z
73GF Score
Jazz Pharmaceuticals PLC HAM:J7Z
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jazz Pharmaceuticals (HAM:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €209.50 is trading 64.9% above its estimated GF Value™ of €127.01. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HAM:J7Z:

  • Valuation Rank:
  • GF Value™: €127.01 vs. price of €209.50 (64.9% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the HAM:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for HAM:J7Z

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€209.50
Price
€127.01
GF Value